Projects funded by the NCN
Syntetyczna letalność w komórkach nowotworowych indukowana inhibitorami białek naprawy pęknięć DNA
2018/28/T/NZ7/00105
Keywords:
Descriptors:
- NZ7_12: Prevention of human diseases
- NZ7_14: Pharmacy, pharmacotherapy, pharmacology
Panel:
NZ7 - Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution :
Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska
woj. łódzkie
Principal investigator (from the host institution):
Number of co-investigators in the project: 2
Call: ETIUDA 6 - announced on 2017-12-15
Amount awarded: 115 676 PLN
Project start date (Y-m-d): 2018-10-01
Project end date (Y-m-d): 2019-09-30
Project duration:: 12 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (2)
- RAD52 as a Potential Target for Synthetic Lethality-Based Anticancer TherapiesAuthors:Monika Toma, Katherine Sullivan-Reed, Tomasz Śliwiński, Tomasz SkorskiAcademic press:Cancers (rok: 2019, tom: 11, strony: 1561), Wydawca: MDPIStatus:PublishedDOI:10.3390/cancers11101561 - link to the publication
- Novel allosteric PARP1 inhibitors for the treatment of BRCA-deficient leukemiaAuthors:Elizabeth Hewlett, Monika Toma, Katherine Sullivan-Reed, John Gordon, Tomasz Sliwinski, Alexei Tulin, Wayne E. Childers, Tomasz SkorskiAcademic press:Medicinal Chemistry Research (rok: 2020, tom: 29, strony: 962-978), Wydawca: SpringerStatus:PublishedDOI:10.1007/s00044-020-02537-0 - link to the publication